Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Key facts

Sponsor

Sellas Life Sciences Group

Principal Investigator

Dragan Cicic Chief Development Officer, MD

Sellas Life Sciences Group

Intervention

Galinpepimut-S(biological)

Enrollment

127 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2026

Study locations (30)

• O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
• UCLA Medical Hematology and Oncology, Los Angeles, California, United States
• The Oncology Institute of Hope and Innovation, Whittier, California, United States
• Colorado Blood Cancer Institute - SCRI - PPDS, Denver, Colorado, United States
• Mayo Clinic Jacksonville Florida, Jacksonville, Florida, United States
• Augusta University, Augusta, Georgia, United States
• Rush University Cancer Center, Chicago, Illinois, United States
• Tulane Cancer Center - Liberty, New Orleans, Louisiana, United States
• Northwell Health Cancer Institute, Lake Success, New York, United States
• New York Medical College, Valhalla, New York, United States
• University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
• Oregon Health and Science University, Portland, Oregon, United States
• Bon Secours St. Francis Cancer Center, Greenville, South Carolina, United States
• Baylor Scott and White Research Institute, Dallas, Texas, United States
• University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

PPD Development, LP

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute myeloid leukemia with 11q23 abnormalities

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06710418
  Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
  University of Washington
• RECRUITINGPHASE3NCT07007312
  Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
  Kura Oncology, Inc.
• RECRUITINGPHASE1, PHASE2NCT06928662
  Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
  Fred Hutchinson Cancer Center
• RECRUITINGPHASE1NCT07106749
  CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
  Institute of Hematology & Blood Diseases Hospital, China
• RECRUITINGPHASE1NCT06448013
  A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia
  M.D. Anderson Cancer Center
• RECRUITINGPHASE1NCT06245746
  UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
• RECRUITINGNCT06452732
  Using Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
  Peking University People's Hospital
• RECRUITINGNCT06458257
  The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
  Ruijin Hospital

See all trials for Acute myeloid leukemia with 11q23 abnormalities →